• Gilead Sciences, Inc. is trading 2.4% up at $47,740.00 today, following the U.S. FDA's acceptance of its supplemental New Drug Application (sNDA) for Yeztugo (lenacapavir) 300-mg tablet.
  • This investigational once-weekly oral formulation is for the prevention of HIV as pre-exposure prophylaxis (PrEP), marking a potentially significant advancement in HIV prevention.
  • The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027.